section name header

Pronunciation ⬇

pa-TIR-oh-mer

Classifications ⬆ ⬇

Therapeutic Classification: antidotes, electrolyte modifiers

Pharmacologic Classification: cationic exchange resins

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Contains calcium-sorbitol counterion and ↑ fecal potassium excretion through binding of potassium in the lumen of the GI tract.
Therapeutic effects:
  • Reduced serum potassium concentrations.

Pharmacokinetics ⬆ ⬇

Absorption: Not systemically absorbed.

Distribution: Not distributed.

Metabolism/Excretion: Eliminated in the feces.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(↓ in serum potassium concentrations)
ROUTEONSETPEAKDURATION
PO7–12 hrunknown24 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

F and E: hypokalemia, hypomagnesemia

GI: constipation, diarrhea, flatulence, nausea

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Veltassa